Tevogen Bio is a clinical-stage biotech developing off-the-shelf, allogeneic CD8+ cytotoxic T lymphocyte (CTL) therapies — essentially "killer T cells" harvested from healthy donors, trained to recognize diseased cells, and pre-manufactured in bulk for any compatible patient. Unlike autologous CAR-T therapies, which require harvesting and engineering each patient's own cells, Tevogen's ExacTcell platform produces therapies that are non-genetically modified and available off-the-shelf, which Tevogen argues reduces costs, speeds deployment, and lowers the risk of serious side effects associated with CAR-T. Tevogen's lead candidate, TVGN 489, is a CTL therapy targeting multiple peptide sequences across the SARS-CoV-2 genome, developed primarily for immunocompromised patients who cannot mount an adequate immune response to COVID-19. TVGN 489 completed a Phase 1 trial in early 2023 with no dose-limiting toxicities and encouraging results; a pivotal trial is planned. Beyond COVID-19, Tevogen is applying ExacTcell to HPV-related cancers, EBV-associated lymphomas, EBV-linked multiple sclerosis, and chronic hepatitis B, all at preclinical or discovery stage. Tevogen has no approved products and no revenue, funded entirely by capital raises since going public via SPAC in early 2024. If products reach commercialization, Tevogen would sell pre-manufactured CTL products to hospitals and clinics, offering HLA-matched product panels designed to cover the majority of the population.